CANCER RESEARCH AMERICA NFCR INC: Form 990, tax year 2010
View the entire original 990 at ProPublica ↗
- Organization
- CANCER RESEARCH AMERICA NFCR INC (EIN 04-2531031)
- Tax period
- 2010-01-01 to 2010-12-31
- Filed
- 2011-08-05
- IRS object ID
- 201142179349300754
- Schema version
- 2010v3.4
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Timestamp | 2011-08-05T08:28:08-05:00 | Timestamp |
| Tax Period End Date | 2010-12-31 | TaxPeriodEndDate |
Preparer Firm PreparerFirm
Preparer Firm Business Name PreparerFirmBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | SQUIRE LEMKIN COMPANY LLP | BusinessNameLine1 |
Preparer Firm US Address PreparerFirmUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 111 ROCKVILLE PIKE SUITE 475 | AddressLine1 |
| City | ROCKVILLE | City |
| State | MD | State |
| ZIP Code | 20850 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnType |
| Tax Period Begin Date | 2010-01-01 | TaxPeriodBeginDate |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 042531031 | EIN |
Name Name
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | NATIONAL FOUNDATION FOR CANCER RESEARCH | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Control | NATI | NameControl |
| Phone | 3016541250 | Phone |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4600 EAST-WEST HIGHWAY NO 525 | AddressLine1 |
| City | BETHESDA | City |
| State | MD | State |
| ZIP Code | 20814 | ZIPCode |
Officer Officer
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name | FRANKLIN SALISBURY | Name |
| Title | CEO | Title |
| Phone | 3016541250 | Phone |
| Date Signed | 2011-07-29 | DateSigned |
| Authorize Third Party | 1 | AuthorizeThirdParty |
Preparer Preparer
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name | CLINT LEHMAN | Name |
| Phone | 3014246800 | Phone |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax Year | 2010 | TaxYear |
| Build TS | 2016-02-24 21:20:13Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Of Principal Officer Person | FRANKLIN SALISBURY | NameOfPrincipalOfficerPerson |
Address Principal Officer US AddressPrincipalOfficerUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4600 EAST-WEST HIGHWAY NO 525 | AddressLine1 |
| City | BETHESDA | City |
| State | MD | State |
| ZIP Code | 20814 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | 19575131 | GrossReceipts |
| Group Return For Affiliates | 0 | GroupReturnForAffiliates |
| Organization501c3 | X | Organization501c3 |
| Web Site | WWW.NFCR.ORG | WebSite |
| Type Of Organization Corporation | X | TypeOfOrganizationCorporation |
| Year Formation | 1973 | YearFormation |
| State Legal Domicile | MA | StateLegalDomicile |
| Activity Or Mission Description | TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER. NFCR PROMOTES AND FACILITATES COLLABORATION AMONG SCIENTISTS TO ACCELERATE THE PACE OF DISCOVERY FROM BENCH TO BEDSIDE. NFCR IS COMMITTED TO RESEARCH FOR A CURE - CURES FOR ALL TYPES OF CANCER. | ActivityOrMissionDescription |
| Nbr Voting Members Governing Body | 6 | NbrVotingMembersGoverningBody |
| Nbr Independent Voting Members | 6 | NbrIndependentVotingMembers |
| Total Nbr Employees | 23 | TotalNbrEmployees |
| Total Nbr Volunteers | 30 | TotalNbrVolunteers |
| Total Gross UBI | 6445 | TotalGrossUBI |
| Net Unrelated Business Txbl Income | 4557 | NetUnrelatedBusinessTxblIncome |
| Contributions Grants Prior Year | 3460179 | ContributionsGrantsPriorYear |
| Contributions Grants Current Year | 13617695 | ContributionsGrantsCurrentYear |
| Program Service Revenue Prior Year | 0 | ProgramServiceRevenuePriorYear |
| Program Service Revenue CY | 0 | ProgramServiceRevenueCY |
| Investment Income Prior Year | 131265 | InvestmentIncomePriorYear |
| Investment Income Current Year | 368774 | InvestmentIncomeCurrentYear |
| Other Revenue Prior Year | 197390 | OtherRevenuePriorYear |
| Other Revenue Current Year | 645812 | OtherRevenueCurrentYear |
| Total Revenue Prior Year | 3788834 | TotalRevenuePriorYear |
| Total Revenue Current Year | 14632281 | TotalRevenueCurrentYear |
| Grants And Similar Amnts Prior Year | 696432 | GrantsAndSimilarAmntsPriorYear |
| Grants And Similar Amnts CY | 2800405 | GrantsAndSimilarAmntsCY |
| Benefits Paid To Members Prior Year | 0 | BenefitsPaidToMembersPriorYear |
| Benefits Paid To Members CY | 0 | BenefitsPaidToMembersCY |
| Salaries Etc Prior Year | 521113 | SalariesEtcPriorYear |
| Salaries Etc Current Year | 2084851 | SalariesEtcCurrentYear |
| Total Prof Fundrsng Exp Prior Year | 90158 | TotalProfFundrsngExpPriorYear |
| Total Prof Fundrsng Exp CY | 144233 | TotalProfFundrsngExpCY |
| Total Fundrsng Exp Current Year | 3828186 | TotalFundrsngExpCurrentYear |
| Other Expense Prior Year | 2408781 | OtherExpensePriorYear |
| Other Expenses Current Year | 9850670 | OtherExpensesCurrentYear |
| Total Expenses Prior Year | 3716484 | TotalExpensesPriorYear |
| Total Expenses Current Year | 14880159 | TotalExpensesCurrentYear |
| Revenues Less Expenses Prior Year | 72350 | RevenuesLessExpensesPriorYear |
| Revenues Less Expenses CY | -247878 | RevenuesLessExpensesCY |
| Total Assets BOY | 10161747 | TotalAssetsBOY |
| Total Assets EOY | 11528826 | TotalAssetsEOY |
| Total Liabilities BOY | 1729036 | TotalLiabilitiesBOY |
| Total Liabilities EOY | 2882848 | TotalLiabilitiesEOY |
| Net Assets Or Fund Balances BOY | 8432711 | NetAssetsOrFundBalancesBOY |
| Net Assets Or Fund Balances EOY | 8645978 | NetAssetsOrFundBalancesEOY |
| Info In Schedule O Part III | X | InfoInScheduleOPartIII |
| Mission Description | TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER. NFCR PROMOTES AND FACILITATES COLLABORATION AMONG SCIENTISTS TO ACCELERATE THE PACE OF DISCOVERY FROM BENCH TO BEDSIDE. NFCR IS COMMITTED TO RESEARCH FOR A CURE - CURES FOR ALL TYPES OF CANCER. | MissionDescription |
| Significant New Program Services | 0 | SignificantNewProgramServices |
| Significant Change | 0 | SignificantChange |
| Expense | 4820038 | Expense |
| Description | CANCER RESEARCH - SEE SCHEDULE O | Description |
Activity2 Activity2
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | 5425946 | Expense |
| Description | CANCER PREVENTION EDUCATION TO THE PUBLIC - SEE SCHEDULE O | Description |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Expense | 10245984 | TotalProgramServiceExpense |
| Described In501 C3 | 1 | DescribedIn501C3 |
| Schedule B Required | 1 | ScheduleBRequired |
| Political Activities | 0 | PoliticalActivities |
| Lobbying Activities | 0 | LobbyingActivities |
| Donor Advised Funds | 1 | DonorAdvisedFunds |
| Conservation Easements | 0 | ConservationEasements |
| Collections Of Art | 0 | CollectionsOfArt |
| Credit Counseling | 0 | CreditCounseling |
| Term Or Permanent Endowments | 1 | TermOrPermanentEndowments |
| Report Land Bldg Equip | 1 | ReportLandBldgEquip |
| Report Invest Oth Securities | 0 | ReportInvestOthSecurities |
| Report Prog Rel Invest | 0 | ReportProgRelInvest |
| Report Other Assets | 1 | ReportOtherAssets |
| Report Other Liabilities | 0 | ReportOtherLiabilities |
| Report Fin48 Footnote | 0 | ReportFin48Footnote |
| Independent Audit Financial Stmt | 0 | IndependentAuditFinancialStmt |
| Consolidated Audit Financial Stmt | 1 | ConsolidatedAuditFinancialStmt |
| School | 0 | School |
| Foreign Office | 0 | ForeignOffice |
| Foreign Activities | 0 | ForeignActivities |
| More Than5000 K To Organizations | 1 | MoreThan5000KToOrganizations |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividuals |
| Professional Fundraising | 1 | ProfessionalFundraising |
| Fundraising Activities | 1 | FundraisingActivities |
| Gaming | 0 | Gaming |
| Hospital | 0 | Hospital |
| Grants To Organizations | 1 | GrantsToOrganizations |
| Grants To Individuals | 1 | GrantsToIndividuals |
| Schedule J Required | 1 | ScheduleJRequired |
| Tax Exempt Bonds | 0 | TaxExemptBonds |
| Excess Benefit Transaction | 0 | ExcessBenefitTransaction |
| Prior Excess Benefit Transaction | 0 | PriorExcessBenefitTransaction |
| Loan To Officer Or DQP | 0 | LoanToOfficerOrDQP |
| Grant To Related Person | 0 | GrantToRelatedPerson |
| Bsnss Rltnshp With Organization | 0 | BsnssRltnshpWithOrganization |
| Bsnss Rltnshp Thru Family Member | 0 | BsnssRltnshpThruFamilyMember |
| Officer Entity With Bsnss Rltnshp | 0 | OfficerEntityWithBsnssRltnshp |
| Deductible Non Cash Contributions | 1 | DeductibleNonCashContributions |
| Deductible Contributions Of Art | 0 | DeductibleContributionsOfArt |
| Terminated | 0 | Terminated |
| Partial Liquidation | 0 | PartialLiquidation |
| Disregarded Entity | 0 | DisregardedEntity |
| Related Entity | 1 | RelatedEntity |
| Related Org Controlled Entity | 0 | RelatedOrgControlledEntity |
| Transaction Related Entity | 0 | TransactionRelatedEntity |
| Transfers To Exempt Non Chrtbl Org | 0 | TransfersToExemptNonChrtblOrg |
| Activities Conducted Partnership | 0 | ActivitiesConductedPartnership |
| Schedule O Required | 1 | ScheduleORequired |
| Number Forms Transmitted With1096 | 9 | NumberFormsTransmittedWith1096 |
| Number W2 G Included | 0 | NumberW2GIncluded |
| Compliance With Backup Witholding | 1 | ComplianceWithBackupWitholding |
| Number Of Employees | 23 | NumberOfEmployees |
| Employment Tax Returns Filed | 1 | EmploymentTaxReturnsFiled |
| Unrelated Business Income | 1 | UnrelatedBusinessIncome |
| Form990-T Filed | 1 | Form990-TFiled |
| Foreign Financial Account | 1 | ForeignFinancialAccount |
| Name Of Foreign Country | HK | NameOfForeignCountry |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTrans |
| Taxable Party Notification | 0 | TaxablePartyNotification |
| Non Deductible Contributions | 0 | NonDeductibleContributions |
| Quid Pro Quo Contributions | 1 | QuidProQuoContributions |
| Quid Pro Quo Disclosure | 1 | QuidProQuoDisclosure |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOf |
| Funds To Pay Premiums | 0 | FundsToPayPremiums |
| Premiums Paid | 0 | PremiumsPaid |
| Excess Business Holdings | 0 | ExcessBusinessHoldings |
| Taxable Distributions | 0 | TaxableDistributions |
| Distribution To Donor | 0 | DistributionToDonor |
| Indoor Tanning Services | 0 | IndoorTanningServices |
| Info In Schedule O Part VI | X | InfoInScheduleOPartVI |
| Nbr Voting Governing Body Members | 6 | NbrVotingGoverningBodyMembers |
| Number Independent Voting Members | 6 | NumberIndependentVotingMembers |
| Family Or Business Relationship | 1 | FamilyOrBusinessRelationship |
| Delegation Of Management Duties | 0 | DelegationOfManagementDuties |
| Changes To Organizing Docs | 0 | ChangesToOrganizingDocs |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuse |
| Members Or Stockholders | 0 | MembersOrStockholders |
| Election Of Board Members | 0 | ElectionOfBoardMembers |
| Decisions Subject To Approval | 0 | DecisionsSubjectToApproval |
| Minutes Of Governing Body | 1 | MinutesOfGoverningBody |
| Minutes Of Committees | 1 | MinutesOfCommittees |
| Officer Mailing Address | 0 | OfficerMailingAddress |
| Local Chapters | 1 | LocalChapters |
| Policies Reference Chapters | 0 | PoliciesReferenceChapters |
| Form990 Provided To Governing Body | 1 | Form990ProvidedToGoverningBody |
| Conflict Of Interest Policy | 1 | ConflictOfInterestPolicy |
| Annual Disclosure Covered Persons | 1 | AnnualDisclosureCoveredPersons |
| Regular Monitoring Enforcement | 1 | RegularMonitoringEnforcement |
| Whistleblower Policy | 1 | WhistleblowerPolicy |
| Document Retention Policy | 1 | DocumentRetentionPolicy |
| Compensation Process CEO | 1 | CompensationProcessCEO |
| Compensation Process Other | 1 | CompensationProcessOther |
| Investment In Joint Venture | 0 | InvestmentInJointVenture |
| States Where Copy Of Return Is Filed | AL | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | AK | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | AZ | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | CA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | CO | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | CT | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | FL | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | GA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | IL | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | KS | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | KY | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | ME | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | MD | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | MA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | MI | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | MN | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | MS | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | NH | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | NJ | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | NM | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | NY | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | NC | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | ND | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | OH | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | OR | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | PA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | RI | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | SC | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | TN | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | UT | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | VA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | WA | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | WV | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | WI | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | AR | StatesWhereCopyOfReturnIsFiled |
| States Where Copy Of Return Is Filed | HI | StatesWhereCopyOfReturnIsFiled |
| Own Website | X | OwnWebsite |
| Other Website | X | OtherWebsite |
| Upon Request | X | UponRequest |
The Books Are In Care Of TheBooksAreInCareOf
Name Business NameBusiness
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | SUJUAN BA | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Telephone Number | 3016541250 | TelephoneNumber |
Address US AddressUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4600 EAST-WEST HIGHWAY NO 525 | AddressLine1 |
| City | BETHESDA | City |
| State | MD | State |
| ZIP Code | 20814 | ZIPCode |
Form990 Part VII Section A Form990PartVIISectionA (10 entries)
| TitleTitle | Average Hours Per WeekAverageHoursPerWeek | Individual Trustee Or DirectorIndividualTrusteeOrDirector | Reportable Comp From OrganizationReportableCompFromOrganization | Reportable Comp From Related OrgsReportableCompFromRelatedOrgs | Other CompensationOtherCompensation | OfficerOfficer | Key EmployeeKeyEmployee | Highest Compensated EmployeeHighestCompensatedEmployee |
|---|---|---|---|---|---|---|---|---|
| MARK BARAN | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| JUDITH P BARNHARD | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | X | ||
| MICHAEL BURKE | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | X | ||
| SCOTT E COLERIDGE | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| PADMAKUMAR KAIMAL | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| RICHARD PERRY | ||||||||
| DIRECTOR | 2.00 | X | 0 | 0 | 0 | |||
| FRANKLIN C SALISBURY JR | ||||||||
| PRESIDENT/CEO | 40.00 | 278363 | 0 | 52629 | X | |||
| SUJUAN BA | ||||||||
| COO/CFO/SECRETARY | 40.00 | 262096 | 0 | 52227 | X | |||
| SREEKUMAR RAGHAVAKAIMAL | ||||||||
| SR VP OF DEVELOPMENT | 40.00 | 197847 | 0 | 42434 | X | |||
| YI WANG | ||||||||
| CHIEF SCIENCE OFFICER | 40.00 | 144545 | 0 | 29953 | X | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | 882851 | TotalReportableCompFromOrg |
| Total Reportable Comp Frm Rltd Orgs | 0 | TotalReportableCompFrmRltdOrgs |
| Total Other Compensation | 177243 | TotalOtherCompensation |
| Number Individuals GT100 K | 4 | NumberIndividualsGT100K |
| Formers Listed | 0 | FormersListed |
| Total Comp GT150 K | 1 | TotalCompGT150K |
| Compensation From Other Sources | 0 | CompensationFromOtherSources |
Contractor Compensation ContractorCompensation (2 entries)
| Address Line1AddressOfContractor/AddressUS/AddressLine1 | CityAddressOfContractor/AddressUS/City | StateAddressOfContractor/AddressUS/State | ZIP CodeAddressOfContractor/AddressUS/ZIPCode | Description Of ServicesDescriptionOfServices | CompensationCompensation |
|---|---|---|---|---|---|
| MERKLE RESPONSE SERVICES | |||||
| 100 JAMISON COURT | HAGERSTOWN | MD | 21740 | LOCKBOX | 204023 |
| MERKLE INC | |||||
| 7001 COLUMBIA GATEWAY DRIVE | COLUMBIA | MD | 21046 | DIRECT MARKETING | 158004 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Number Of Contractors GT100 K | 2 | NumberOfContractorsGT100K |
| Federated Campaigns | 257347 | FederatedCampaigns |
| Fundraising Events | 136732 | FundraisingEvents |
| All Other Contributions | 13223616 | AllOtherContributions |
| Noncash Contributions | 973956 | NoncashContributions |
| Total Contributions | 13617695 | TotalContributions |
Investment Income InvestmentIncome
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 324730 | TotalRevenueColumn |
| Exclusion | $324,730 | ExclusionAmount |
Royalties Revenue RoyaltiesRevenue
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 19707 | TotalRevenueColumn |
| Unrelated Business Revenue | 3640 | UnrelatedBusinessRevenue |
| Exclusion | $16,067 | ExclusionAmount |
Gross Amount Sales Assets GrossAmountSalesAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | 4924347 | Securities |
Less Cost Oth Basis Sales Expenses LessCostOthBasisSalesExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | 4880303 | Securities |
Gain Or Loss GainOrLoss
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | 44044 | Securities |
Net Gain Or Loss Investments NetGainOrLossInvestments
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 44044 | TotalRevenueColumn |
| Exclusion | $44,044 | ExclusionAmount |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Income Fundraising Events | 20700 | GrossIncomeFundraisingEvents |
| Cntrbtns Rprtd Fundraising Events | 136732 | CntrbtnsRprtdFundraisingEvents |
| Fundraising Direct Expenses | 62547 | FundraisingDirectExpenses |
Net Income From Fundraising Events NetIncomeFromFundraisingEvents
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -41847 | TotalRevenueColumn |
| Exclusion | -$41,847 | ExclusionAmount |
Other Revenue Misc OtherRevenueMisc (2 entries)
| DescriptionDescription | Business CodeBusinessCode | Total Revenue ColumnTotalRevenueColumn | Related Or Exempt Function IncomeRelatedOrExemptFunctionIncome | Unrelated Business RevenueUnrelatedBusinessRevenue |
|---|---|---|---|---|
| MAILING LIST RENTALS | 541800 | 482701 | 479896 | 2805 |
| MARKETING INCOME | 900099 | 185251 | 185251 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Revenue | 667952 | TotalOtherRevenue |
Total Revenue TotalRevenue
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | 14632281 | TotalRevenueColumn |
| Related Or Exempt Function Income | 665147 | RelatedOrExemptFunctionIncome |
| Unrelated Business Revenue | 6445 | UnrelatedBusinessRevenue |
| Exclusion | $342,994 | ExclusionAmount |
Grants To Domestic Orgs GrantsToDomesticOrgs
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 2516715 | Total |
| Program Services | 2516715 | ProgramServices |
Grants To Domestic Individuals GrantsToDomesticIndividuals
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 25000 | Total |
| Program Services | 25000 | ProgramServices |
Foreign Grants ForeignGrants
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 258690 | Total |
| Program Services | 258690 | ProgramServices |
Comp Current Officers Directors CompCurrentOfficersDirectors
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 903233 | Total |
| Program Services | 798479 | ProgramServices |
| Management And General | 67280 | ManagementAndGeneral |
| Fundraising | 37474 | Fundraising |
Other Salaries And Wages OtherSalariesAndWages
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 882209 | Total |
| Program Services | 597386 | ProgramServices |
| Management And General | 220271 | ManagementAndGeneral |
| Fundraising | 64552 | Fundraising |
Pension Plan Contributions PensionPlanContributions
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 95657 | Total |
| Program Services | 60290 | ProgramServices |
| Management And General | 27334 | ManagementAndGeneral |
| Fundraising | 8033 | Fundraising |
Other Employee Benefits OtherEmployeeBenefits
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 114621 | Total |
| Program Services | 85897 | ProgramServices |
| Management And General | 22207 | ManagementAndGeneral |
| Fundraising | 6517 | Fundraising |
Payroll Taxes PayrollTaxes
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 89131 | Total |
| Program Services | 68880 | ProgramServices |
| Management And General | 15111 | ManagementAndGeneral |
| Fundraising | 5140 | Fundraising |
Fees For Services Legal FeesForServicesLegal
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 72432 | Total |
| Program Services | 5662 | ProgramServices |
| Management And General | 66770 | ManagementAndGeneral |
Fees For Services Accounting FeesForServicesAccounting
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 41145 | Total |
| Management And General | 41145 | ManagementAndGeneral |
Fees For Services Prof Fundraising FeesForServicesProfFundraising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 144233 | Total |
| Fundraising | 144233 | Fundraising |
Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 52786 | Total |
| Management And General | 52786 | ManagementAndGeneral |
Fees For Services Other FeesForServicesOther
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 156549 | Total |
| Program Services | 146551 | ProgramServices |
| Management And General | 2924 | ManagementAndGeneral |
| Fundraising | 7074 | Fundraising |
Advertising Advertising
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 566 | Total |
| Management And General | 566 | ManagementAndGeneral |
Office Expenses OfficeExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 266958 | Total |
| Program Services | 61492 | ProgramServices |
| Management And General | 182952 | ManagementAndGeneral |
| Fundraising | 22514 | Fundraising |
Information Technology InformationTechnology
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 410091 | Total |
| Program Services | 241441 | ProgramServices |
| Management And General | 11444 | ManagementAndGeneral |
| Fundraising | 157206 | Fundraising |
Occupancy Occupancy
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 318185 | Total |
| Program Services | 245979 | ProgramServices |
| Management And General | 53604 | ManagementAndGeneral |
| Fundraising | 18602 | Fundraising |
Travel Travel
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 102442 | Total |
| Program Services | 89341 | ProgramServices |
| Management And General | 13101 | ManagementAndGeneral |
Conferences Meetings ConferencesMeetings
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 22791 | Total |
| Program Services | 4357 | ProgramServices |
| Management And General | 17936 | ManagementAndGeneral |
| Fundraising | 498 | Fundraising |
Depreciation Depletion DepreciationDepletion
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 29596 | Total |
| Program Services | 22875 | ProgramServices |
| Management And General | 4992 | ManagementAndGeneral |
| Fundraising | 1729 | Fundraising |
Insurance Insurance
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 31478 | Total |
| Program Services | 24324 | ProgramServices |
| Management And General | 5314 | ManagementAndGeneral |
| Fundraising | 1840 | Fundraising |
Other Expenses OtherExpenses (4 entries)
| DescriptionDescription | TotalTotal | Program ServicesProgramServices | FundraisingFundraising | Management And GeneralManagementAndGeneral |
|---|---|---|---|---|
| DIRECT MAIL PROGRAMS | 7264797 | 4004311 | 3260486 | |
| NON-CASH DONATION | 850128 | 850128 | ||
| LOCK BOX SERVICE | 204741 | 114681 | 90060 | |
| WEBSITE | 25985 | 23505 | 2228 | 252 |
Total Functional Expenses TotalFunctionalExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 14880159 | Total |
| Program Services | 10245984 | ProgramServices |
| Management And General | 805989 | ManagementAndGeneral |
| Fundraising | 3828186 | Fundraising |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Joint Costs | X | JointCosts |
Total Joint Costs TotalJointCosts
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | 7711670 | Total |
| Program Services | 4427550 | ProgramServices |
| Management And General | 250 | ManagementAndGeneral |
| Fundraising | 3283870 | Fundraising |
Cash Non Interest Bearing CashNonInterestBearing
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 988 | BOY |
| EOY | 1000 | EOY |
Savings And Temp Cash Investments SavingsAndTempCashInvestments
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 699109 | BOY |
| EOY | 1398980 | EOY |
Pledges And Grants Receivable PledgesAndGrantsReceivable
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 16333 | BOY |
Accounts Receivable AccountsReceivable
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 330113 | BOY |
| EOY | 366415 | EOY |
Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 267219 | BOY |
| EOY | 208943 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Buildings Equipment Basis | 343336 | LandBuildingsEquipmentBasis |
| Land Bldg Equipment Accum Deprec | 280002 | LandBldgEquipmentAccumDeprec |
Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 76611 | BOY |
| EOY | 63334 | EOY |
Investments Pub Traded Securities InvestmentsPubTradedSecurities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 6721224 | BOY |
| EOY | 7267315 | EOY |
Investments Other Securities InvestmentsOtherSecurities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 441267 | BOY |
| EOY | 496648 | EOY |
Other Assets Total OtherAssetsTotal
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 1608883 | BOY |
| EOY | 1726191 | EOY |
Total Assets TotalAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 10161747 | BOY |
| EOY | 11528826 | EOY |
Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 1329036 | BOY |
| EOY | 2636891 | EOY |
Grants Payable GrantsPayable
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 400000 | BOY |
| EOY | 245822 | EOY |
Deferred Revenue DeferredRevenue
| Field | Value | IRS element (for citing) |
|---|---|---|
| EOY | 135 | EOY |
Total Liabilities TotalLiabilities
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 1729036 | BOY |
| EOY | 2882848 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Follow SFAS117 | X | FollowSFAS117 |
Unrestricted Net Assets UnrestrictedNetAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 5954714 | BOY |
| EOY | 6501706 | EOY |
Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 1083077 | BOY |
| EOY | 652303 | EOY |
Permanently Restricted Net Assets PermanentlyRestrictedNetAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 1394920 | BOY |
| EOY | 1491969 | EOY |
Total Net Assets Fund Balances TotalNetAssetsFundBalances
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 8432711 | BOY |
| EOY | 8645978 | EOY |
Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | 10161747 | BOY |
| EOY | 11528826 | EOY |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | X | InfoInScheduleOPartXI |
| Reconcilation Revenue Expenses | -247878 | ReconcilationRevenueExpenses |
| Reconcilation Other Changes | 461145 | ReconcilationOtherChanges |
| Method Of Accounting Accrual | X | MethodOfAccountingAccrual |
| Accountant Compile Or Review | 0 | AccountantCompileOrReview |
| FS Audited | 1 | FSAudited |
| Audit Committee | 1 | AuditCommittee |
| Financial Statement Consolidated | X | FinancialStatementConsolidated |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequired |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Publicly Supported Org170b1 Avi | X | PubliclySupportedOrg170b1Avi |
Gifts Grants Contrib Received170 GiftsGrantsContribReceived170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 16724026 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 14878740 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 13577309 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 3460179 | CurrentTaxYearMinus1Year |
| Current Tax Year | 13617695 | CurrentTaxYear |
| Total | 62257949 | Total |
Total170 Total170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 16724026 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 14878740 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 13577309 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 3460179 | CurrentTaxYearMinus1Year |
| Current Tax Year | 13617695 | CurrentTaxYear |
| Total | 62257949 | Total |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Amounts Subst Contributors Total | 590659 | AmountsSubstContributorsTotal |
| Public Support Total170 | 61667290 | PublicSupportTotal170 |
Gross Investment Income170 GrossInvestmentIncome170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | 1082178 | CurrentTaxYearMinus4Years |
| Current Tax Year Minus3 Years | 1100500 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | -11167 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 131265 | CurrentTaxYearMinus1Year |
| Current Tax Year | 368774 | CurrentTaxYear |
| Total | 2671550 | Total |
Other Income170 OtherIncome170
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus3 Years | 592364 | CurrentTaxYearMinus3Years |
| Current Tax Year Minus2 Years | 501961 | CurrentTaxYearMinus2Years |
| Current Tax Year Minus1 Year | 197390 | CurrentTaxYearMinus1Year |
| Current Tax Year | 645812 | CurrentTaxYear |
| Total | 1937527 | Total |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | 66867026 | TotalSupport |
| Public Support Pertcentage170 | 0.92220 | PublicSupportPertcentage170 |
| Public Support Pertcent Prior Year | 0.87710 | PublicSupportPertcentPriorYear |
| Thirty Three Percnt Tests CY170 | X | ThirtyThreePercntTestsCY170 |
Schedule B IRS990ScheduleB
Contributor Info ContributorInfo
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor Number | RESTRICTED | ContributorNumber |
Contributor Name Business ContributorNameBusiness
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor Address US ContributorAddressUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Aggregate Contributions | RESTRICTED | AggregateContributions |
Schedule D IRS990ScheduleD
| Field | Value | IRS element (for citing) |
|---|---|---|
| Number DA Fs Held | 1 | NumberDAFsHeld |
| Donor Advised Contributions | 12934 | DonorAdvisedContributions |
| Grants Paid From Donor Funds | 28928 | GrantsPaidFromDonorFunds |
| Aggregate DAF Value | 300 | AggregateDAFValue |
| Disclosed Orgs Legal Control | 1 | DisclosedOrgsLegalControl |
| Disclosed For Charitable Purposes | 1 | DisclosedForCharitablePurposes |
Current Year CurrentYear
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Of Year Balance | 7021603 | BeginningOfYearBalance |
| Contributions | 2261795 | Contributions |
| Investment Earnings Or Losses | 117308 | InvestmentEarningsOrLosses |
| Other Expenditures | 2288642 | OtherExpenditures |
| End Of Year Balance | 7112064 | EndOfYearBalance |
Current Year Minus1 Year CurrentYearMinus1Year
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Of Year Balance | 5671862 | BeginningOfYearBalance |
| Contributions | 1882988 | Contributions |
| Investment Earnings Or Losses | 26552 | InvestmentEarningsOrLosses |
| Other Expenditures | 559799 | OtherExpenditures |
| End Of Year Balance | 7021603 | EndOfYearBalance |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated EOY Balance | 0.70000 | BoardDesignatedEOYBalance |
| Permanent Endowment EOY Balance | 0.21000 | PermanentEndowmentEOYBalance |
| Term Endowment EOY Balance | 0.09000 | TermEndowmentEOYBalance |
| Endowments Held By Unrelated Orgs | 0 | EndowmentsHeldByUnrelatedOrgs |
| Endowments Held By Related Orgs | 0 | EndowmentsHeldByRelatedOrgs |
Leasehold Improvements LeaseholdImprovements
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | 19786 | OtherCostOrOtherBasis |
| Depreciation | 10552 | Depreciation |
| Book Value | 9234 | BookValue |
Equipment Equipment
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | 323550 | OtherCostOrOtherBasis |
| Depreciation | 269450 | Depreciation |
| Book Value | 54100 | BookValue |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Of Book Value Land Buildings | 63334 | TotalOfBookValueLandBuildings |
Other Assets OtherAssets
| Field | Value | IRS element (for citing) |
|---|---|---|
| Description | AMOUNTS HELD IN TRUSTS BY OTHERS | Description |
| Book Value | 1726191 | BookValue |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Other Assets | 1726191 | TotalBookValueOtherAssets |
| Total Revenue | 14632281 | TotalRevenue |
| Total Expenses | 14880159 | TotalExpenses |
| Excess Or Deficit For Year | -247878 | ExcessOrDeficitForYear |
| Net Unrealized GL On Investments | 461145 | NetUnrealizedGLOnInvestments |
| Total Adjustments | 461145 | TotalAdjustments |
| Excess Or Deficit Per FS | 213267 | ExcessOrDeficitPerFS |
| Tot Revenue Etc Audited Fincl Stmt | 15093426 | TotRevenueEtcAuditedFinclStmt |
| Net Unrealized Gains Investments | 461145 | NetUnrealizedGainsInvestments |
| Revenue Not Rptd F990 | 461145 | RevenueNotRptdF990 |
| Revenue Subtotal | 14632281 | RevenueSubtotal |
| Revenue Not Rptd On Fin Stmt | 0 | RevenueNotRptdOnFinStmt |
| Total Revenue Per Form990 | 14632281 | TotalRevenuePerForm990 |
| Tot Expenses Etc Audited Fincl Stmt | 14880159 | TotExpensesEtcAuditedFinclStmt |
| Expenses Not Rptd F990 | 0 | ExpensesNotRptdF990 |
| Expenses Subtotal | 14880159 | ExpensesSubtotal |
| Expenses Not Rptd On Fin Stmt | 0 | ExpensesNotRptdOnFinStmt |
| Total Expenses Per Form990 | 14880159 | TotalExpensesPerForm990 |
Form990 Schedule D Part XIV Form990ScheduleDPartXIV
| Field | Value | IRS element (for citing) |
|---|---|---|
| Identifier | DESCRIPTION OF INTENDED USE OF ENDOWMENT FUNDS: | Identifier |
| Return Reference | PART V, LINE 4: | ReturnReference |
| Explanation | THE PRINCIPAL ACTIVITIES OF NFCR ARE RAISING FUNDS AND FIGHTING CANCER THROUGH RESEARCH IN PREVENTION, EARLIER DIAGNOSTIC TECHNIQUES, MORE EFFECTIVE TREATMENTS AND ULTIMATELY, ACHIEVING ONE OF MEDICINES GREATEST GOALS: CURING CANCER TO SAVE LIVES. THE FOUNDATION FULFILLS THIS MISSION BY FUNDING ACROSS THE WORLD OUTSTANDING SCIENTISTS THAT PIONEER CANCER RESEARCH AND FUNDING CANCER PREVENTION EDUCATION PROGRAMS. THE DESIGNATED NET ASSETS, TEMPORARILY RESTRICTED NET ASSETS, AND PERMANENTLY RESTRICTED NET ASSETS ALL ARE INTENDED TO PROVIDE FUNDING FOR SUCH RESEARCH AND EDUCATION PROGRAMS. | Explanation |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | 1 | GrantRecordsMaintained |
| Subtotal Number Of Employees | 0 | SubtotalNumberOfEmployees |
| Cont Number Of Employees | 0 | ContNumberOfEmployees |
| Total Number Of Employees | 0 | TotalNumberOfEmployees |
| Subtotal Amount Spent | 0 | SubtotalAmountSpent |
| Cont Amount Spent | 0 | ContAmountSpent |
| Total Amount Spent | 0 | TotalAmountSpent |
Grants To Orgs Outside US GrantsToOrgsOutsideUS (6 entries)
| RegionRegion | Purpose Of GrantPurposeOfGrant | Amount Of Cash GrantAmountOfCashGrant | Manner Of Cash DisbursementMannerOfCashDisbursement |
|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) | CANCER RESEARCH | 30000 | WIRE TRANSFER |
| EUROPE (INCLUDING ICELAND & GREENLAND) | CANCER RESEARCH | 50000 | CHECK |
| EUROPE (INCLUDING ICELAND & GREENLAND) | CANCER RESEARCH | 18812 | CHECK |
| EUROPE (INCLUDING ICELAND & GREENLAND) | CANCER CONFERENCE SPONSORSHIP | 5000 | WIRE TRANSFER |
| EAST ASIA AND THE PACIFIC | CANCER RESEARCH | 56950 | CHECK AND WIRE TRANSFER |
| EAST ASIA AND THE PACIFIC | CANCER RESEARCH | 97928 | CHECK |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Number Of501c3 Orgs | 6 | TotalNumberOf501c3Orgs |
| Transfer To Foreign Corp | 0 | TransferToForeignCorp |
| Interest In Foreign Trust | 0 | InterestInForeignTrust |
| Own Foreign Corp | 0 | OwnForeignCorp |
| Passive Foreign Invest Co | 0 | PassiveForeignInvestCo |
| Foreign Partnership | 0 | ForeignPartnership |
| Boycott Countries | 0 | BoycottCountries |
Form990 Schedule F Part V Form990ScheduleFPartV
| Field | Value | IRS element (for citing) |
|---|---|---|
| Identifier | PROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.: | Identifier |
| Explanation | SCHEDULE F, PART I, LINE 2: GRANT AND CONTRACT RECIPIENTS WERE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. | Explanation |
Schedule G IRS990ScheduleG
| Field | Value | IRS element (for citing) |
|---|---|---|
| Mail Solicitations | X | MailSolicitations |
| Email Solicitations | X | EmailSolicitations |
| Phone Solicitations | X | PhoneSolicitations |
| In Person Solicitations | X | InPersonSolicitations |
| Solicitation Of Non Govt Grants | X | SolicitationOfNonGovtGrants |
| Special Fundraising Events | X | SpecialFundraisingEvents |
| Agreement Ref Fundraising | 1 | AgreementRefFundraising |
Fundraiser Activity Information FundraiserActivityInformation
Name Of Organization NameOfOrganization
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | INFOCISION MANAGEMENT CORPORATION | BusinessNameLine1 |
Address US AddressUS
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 325 SPRINGSIDE DRIVE | AddressLine1 |
| City | AKRON | City |
| State | OH | State |
| ZIP Code | 44333 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Activity | TELEMARKETING | Activity |
| Fundraiser Control Of Funds | 0 | FundraiserControlOfFunds |
| Gross Receipts | 58172 | GrossReceipts |
| Amount Retained By Contractor | 33318 | AmountRetainedByContractor |
| Net To Organization | 24854 | NetToOrganization |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Gross Receipts | 58172 | TotalGrossReceipts |
| Total Retained By Contractors | 33318 | TotalRetainedByContractors |
| Total Net To Organization | 24854 | TotalNetToOrganization |
| Licensed States | AL | LicensedStates |
| Licensed States | AK | LicensedStates |
| Licensed States | AZ | LicensedStates |
| Licensed States | AR | LicensedStates |
| Licensed States | CA | LicensedStates |
| Licensed States | CO | LicensedStates |
| Licensed States | CT | LicensedStates |
| Licensed States | DC | LicensedStates |
| Licensed States | FL | LicensedStates |
| Licensed States | GA | LicensedStates |
| Licensed States | HI | LicensedStates |
| Licensed States | IL | LicensedStates |
| Licensed States | IN | LicensedStates |
| Licensed States | KS | LicensedStates |
| Licensed States | KY | LicensedStates |
| Licensed States | ME | LicensedStates |
| Licensed States | MD | LicensedStates |
| Licensed States | MA | LicensedStates |
| Licensed States | MI | LicensedStates |
| Licensed States | MN | LicensedStates |
| Licensed States | MS | LicensedStates |
| Licensed States | NH | LicensedStates |
| Licensed States | NJ | LicensedStates |
| Licensed States | NM | LicensedStates |
| Licensed States | NY | LicensedStates |
| Licensed States | NC | LicensedStates |
| Licensed States | ND | LicensedStates |
| Licensed States | OH | LicensedStates |
| Licensed States | OK | LicensedStates |
| Licensed States | OR | LicensedStates |
| Licensed States | PA | LicensedStates |
| Licensed States | RI | LicensedStates |
| Licensed States | SC | LicensedStates |
| Licensed States | TN | LicensedStates |
| Licensed States | UT | LicensedStates |
| Licensed States | VA | LicensedStates |
| Licensed States | WA | LicensedStates |
| Licensed States | WV | LicensedStates |
| Licensed States | WI | LicensedStates |
Events Information EventsInformation
| Field | Value | IRS element (for citing) |
|---|---|---|
| Name Of Event1 | DC GOLF | NameOfEvent1 |
| Gross Receipts Event1 | 87470 | GrossReceiptsEvent1 |
| Charitable Contributions Event1 | 74270 | CharitableContributionsEvent1 |
| Gross Revenue Event1 | 13200 | GrossRevenueEvent1 |
| Other Direct Expenses Event1 | 36220 | OtherDirectExpensesEvent1 |
| Name Of Event2 | DAFFODILS & DIAMONDS | NameOfEvent2 |
| Gross Receipts Event2 | 69962 | GrossReceiptsEvent2 |
| Charitable Contributions Event2 | 62462 | CharitableContributionsEvent2 |
| Gross Revenue Event2 | 7500 | GrossRevenueEvent2 |
| Other Direct Expenses Event2 | 26327 | OtherDirectExpensesEvent2 |
| Gross Receipts Total | 157432 | GrossReceiptsTotal |
| Charitable Contributions Total | 136732 | CharitableContributionsTotal |
| Gross Revenue Total Events | 20700 | GrossRevenueTotalEvents |
| Other Direct Expenses Total Events | 62547 | OtherDirectExpensesTotalEvents |
| Direct Expense Summary Events | 62547 | DirectExpenseSummaryEvents |
| Net Income Summary | -41847 | NetIncomeSummary |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Records Maintained | 1 | RecordsMaintained |
Recipient Table RecipientTable (24 entries)
| Address Line1AddressUS/AddressLine1 | CityAddressUS/City | StateAddressUS/State | ZIP CodeAddressUS/ZIPCode | Amount Of Cash GrantAmountOfCashGrant | Purpose Of GrantPurposeOfGrant | Address Line2AddressUS/AddressLine2 |
|---|---|---|---|---|---|---|
| THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | ||||||
| 445 NORTH FIFTH ST SUITE 600 | PHOENIX | AZ | 85004 | 168270 | RESEARCH CONTRACTS | |
| THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | ||||||
| 445 NORTH FIFTH ST SUITE 600 | PHOENIX | AZ | 85004 | 80000 | RESEARCH PROJECT - CANCER PATIENT ASSISTANCE FUND | |
| ALBERT EINSTEIN COLLEGE OF MEDICINE | ||||||
| 1300 MORRIS PARK AVE | BRONX | NY | 10461 | 24348 | RESEARCH CONTRACTS | |
| BETH ISRAEL HOSPITAL | ||||||
| 330 BROOKLINE AVE | BOSTON | MA | 02215 | 13078 | RESEARCH CONTRACTS | |
| CASE WESTERN RESERVE UNIVERSITY | ||||||
| 10900 EUCLID AVENUE | CLEVELAND | OH | 44106 | 15118 | RESEARCH CONTRACTS | |
| CHINESE BIOPHARMACEUTICAL ASSOCIATION | ||||||
| P O BOX 61362 | POTOMAC | MD | 20859 | 5000 | EVENT SPONSORSHIP | |
| DANA-FARBER CANCER INSTITUTE | ||||||
| MAIL STOP L229 44 BINNEY ST | BOSTON | MA | 02115 | 6096 | RESEARCH CONTRACTS | |
| DARTMOUTH COLLEGE | ||||||
| 11 ROPE FERRY ROAD 6210 | HANOVER | NH | 03755 | 40536 | RESEARCH CONTRACTS | |
| GEORGETOWN UNIVERSITY | ||||||
| PO BOX 571164 | WASHINGTON | DC | 20057 | 12500 | RESEARCH CONTRACTS | |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||
| PO BOX 414876 | BOSTON | MA | 02241 | 21500 | RESEARCH CONTRACTS | |
| STANFORD UNIVERSITY | ||||||
| PO BOX 44253 | SAN FRANCISCO | CA | 94144 | 14322 | RESEARCH CONTRACTS | |
| CHILDREN RESEARCH INSTITUTE | ||||||
| 700 CHILDRENS DRIVE W155 | COLUMBUS | OH | 43205 | 7674 | RESEARCH CONTRACTS | |
| THE SCRIPPS RESEARCH INSTITUTE | ||||||
| 10550 NORTH TORREY PINES RD | LA JOLLA | CA | 92037 | 393750 | RESEARCH CONTRACTS | |
| UNIVERSITY OF TEXAS - MD ANDERSON CANCER CENTER | ||||||
| PO BOX 4390 | HOUSTON | TX | 77210 | 64465 | RESEARCH CONTRACTS | |
| UNIVERSITY OF CHICAGO | ||||||
| 1170 EAST 58TH STREET | CHICAGO | IL | 60637 | 40000 | RESEARCH CONTRACTS | |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | ||||||
| 1530 3RD AVENUE SOUTH AB 990 | BIRMINGHAM | AL | 35294 | 134464 | RESEARCH CONTRACTS | |
| UNIVERSITY OF CALIFORNIA AT SAN DIEGO | ||||||
| PO BOX 12385 | LA JOLLA | CA | 92093 | 73522 | RESEARCH CONTRACTS | |
| UNIVERSITY OF COLORADO AT DENVER | ||||||
| OFFICE OF GRANTS CONTR F428 | DENVER | CO | 80291 | 18809 | RESEARCH CONTRACTS | DEPARTMENT 238 |
| UNIVERSITY OF MARYLAND | ||||||
| 220 ARCH ST OFFICE LEVEL 2 | BALTIMORE | MD | 21201 | 64586 | RESEARCH CONTRACTS | |
| VANDERBILT UNIVERSITY MEDICAL CENTER | ||||||
| DEPT AT 40303 | ATLANTIC | GA | 31192 | 96948 | RESEARCH CONTRACTS | |
| VIRGINIA COMMONWEALTH UNIVERSITY | ||||||
| PO BOX 980568 | RICHMOND | VA | 23298 | 18282 | RESEARCH CONTRACTS | |
| WAKE FOREST UNIVERSITY | ||||||
| PO BOX 7201 | WINSTOM SALEM | NC | 27109 | 22099 | RESEARCH CONTRACTS | |
| WEILL CORNELL MEDICAL COLLEGE | ||||||
| 100 BROADWAY 8TH FLOOR | NEW YORK | NY | 10005 | 167008 | RESEARCH CONTRACTS | |
| YALE UNIVERSITY | ||||||
| P O BOX 1873 | NEW HAVEN | CT | 06508 | 286391 | RESEARCH CONTRACTS | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Nbr Of501 C3 And Govt Grants | 24 | TotalNbrOf501C3AndGovtGrants |
Form990 Schedule I Part III Form990ScheduleIPartIII
| Field | Value | IRS element (for citing) |
|---|---|---|
| Type Of Grant | ALBERT SZENT-GYORGYI PRIZE | TypeOfGrant |
| Number Of Recipients | 1 | NumberOfRecipients |
| Amount Of Cash Grant | 25000 | AmountOfCashGrant |
Form990 Schedule I Part IV Form990ScheduleIPartIV
| Field | Value | IRS element (for citing) |
|---|---|---|
| Identifier | PROCEDURE FOR MONITORING GRANTS IN THE U.S.: | Identifier |
| Return Reference | PART I, LINE 2: | ReturnReference |
| Explanation | SCHEDULE I, PART I, LINE 2: GRANT AND CONTRACT RECIPIENTS WERE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. | Explanation |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Independent Consultant | X | IndependentConsultant |
| Form990 Of Other Organizations | X | Form990OfOtherOrganizations |
| Compensation Survey | X | CompensationSurvey |
| Board Or Committee Approval | X | BoardOrCommitteeApproval |
| Severance Payment | 0 | SeverancePayment |
| Supplemental Nonqual Retire Plan | 0 | SupplementalNonqualRetirePlan |
| Equity Based Comp Arrangement | 0 | EquityBasedCompArrangement |
| Comp Based On Revenue Of Filing Org | 0 | CompBasedOnRevenueOfFilingOrg |
| Comp Based On Revenue Related Orgs | 0 | CompBasedOnRevenueRelatedOrgs |
| Comp Based Net Earnings Filing Org | 0 | CompBasedNetEarningsFilingOrg |
| Comp Based Net Earnings Relate Orgs | 0 | CompBasedNetEarningsRelateOrgs |
| Any Non Fixed Payments | 0 | AnyNonFixedPayments |
| Initial Contract Exception | 0 | InitialContractException |
Form990 Schedule J Part II Form990ScheduleJPartII (4 entries)
| Base Compensation Filing OrgBaseCompensationFilingOrg | Comp Based On Related OrgsCompBasedOnRelatedOrgs | Bonus Filing OrgBonusFilingOrg | Bonus Related OrgsBonusRelatedOrgs | Other Compensation Filing OrgOtherCompensationFilingOrg | Other Compensation Related OrgsOtherCompensationRelatedOrgs | Deferred Comp Filing OrgDeferredCompFilingOrg | Deferred Comp Related OrgsDeferredCompRelatedOrgs | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg | Nontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgs | Total Compensation Filing OrgTotalCompensationFilingOrg | Total Compensation Related OrgsTotalCompensationRelatedOrgs | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrg | Comp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FRANKLIN C SALISBURY JR | |||||||||||||
| 278363 | 0 | 0 | 0 | 0 | 0 | 45440 | 0 | 7189 | 0 | 330992 | 0 | 0 | 0 |
| SUJUAN BA | |||||||||||||
| 262096 | 0 | 0 | 0 | 0 | 0 | 44584 | 0 | 7643 | 0 | 314323 | 0 | 0 | 0 |
| SREEKUMAR RAGHAVAKAIMAL | |||||||||||||
| 197847 | 0 | 0 | 0 | 0 | 0 | 29942 | 0 | 12492 | 0 | 240281 | 0 | 0 | 0 |
| YI WANG | |||||||||||||
| 144545 | 0 | 0 | 0 | 0 | 0 | 22040 | 0 | 7913 | 0 | 174498 | 0 | 0 | 0 |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTraded
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | X | NonCashCheckbox |
| Number Of Contributions | 8 | NumberOfContributions |
| Noncash Contribs Rptd F990 | 123828 | NoncashContribsRptdF990 |
| Method Of Determining Revenues | FAIR MARKET VALUE | MethodOfDeterminingRevenues |
Other Non Cash Contributions Table OtherNonCashContributionsTable
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | X | NonCashCheckbox |
| Description | COMPUTER EQUIPMENT | Description |
| Number Of Contributions | 17 | NumberOfContributions |
| Noncash Contribs Rptd F990 | 850128 | NoncashContribsRptdF990 |
| Method Of Determining Revenues | FAIR MARKET VALUE | MethodOfDeterminingRevenues |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeld |
| Review Process Unusual NC Gifts | 1 | ReviewProcessUnusualNCGifts |
| Third Parties Used | 0 | ThirdPartiesUsed |
Form990 Schedule M Part II Form990ScheduleMPartII
| Field | Value | IRS element (for citing) |
|---|---|---|
| Identifier | METHOD FOR DETERMINING NUMBER OF CONTRIBUTORS: | Identifier |
| Return Reference | PART I, COLUMN (B): | ReturnReference |
| Explanation | THE NUMBER OF CONTRIBUTORS IS DETERMINED BY THE NUMBER OF INDIVIDUALS OR ORGANIZATIONS WHO DONATED/CONTRIBUTED EQUIPMENT OR STOCKS. | Explanation |
Schedule O IRS990ScheduleO
General Explanation GeneralExplanation (10 entries)
| IdentifierIdentifier | ExplanationExplanation | Return ReferenceReturnReference |
|---|---|---|
| FORM 990, PART VI, SECTION A, LINE 2 | FRANKLIN SALISBURY, PRESIDENT AND CEO, AND SUJUAN BA, COO/CFO/SECRETARY ARE HUSBAND AND WIFE. SREEKUMAR RAGHAVAKIMAL, SENIOR VP OF DEVELOPMENT AND PADMAKUMAR RAGHAVAKAIMAL, BOARD DIRECTOR, ARE BROTHERS. | |
| FORM 990, PART VI, SECTION B, LINE 10B | THE LOCAL CHAPTER HAD LITTLE ACTIVITIES AND A POLICY IS BEING DRAFTED. | |
| FORM 990, PART VI, SECTION B, LINE 11 | THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE 990: 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CONTROLLER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBERS' COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFICIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENCE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILING DEADLINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMBERS' REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN, IF NECESSARY, WILL BE FILED. | |
| EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE CORPORATION HAS, OR MIGHT REASONABLY IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. | FORM 990, PART VI, SECTION B, LINE 12C | |
| ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING 3 ELEMENTS: 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CONTROLLER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION ARRANGEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. | FORM 990, PART VI, SECTION B, LINE 15 | |
| THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDTAION'S WEBSITE. | FORM 990, PART VI, SECTION C, LINE 19 | |
| CHANGES IN NET ASSETS OR FUND BALANCES: | NET UNREALIZED GAINS ON INVESTMENTS: 461,145. | FORM 990, PART XI, LINE 5: |
| PROGRAM DESCRIPTIONS | THE NATIONAL FOUNDATION FOR CANCER RESEARCH (NFCR) IS A LEADING PUBLIC CHARITY DEDICATED TO FUNDING CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO CANCER PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND, ULTIMATELY, CURES FOR CANCER. NFCR PROMOTES AND FACILITATES COLLABORATION AMONG SCIENTISTS TO ACCELERATE THE PACE OF DISCOVERY FROM BENCH TO BEDSIDE. SINCE 1973, NFCR HAS PROVIDED OVER $288 MILLION IN SUPPORT OF DISCOVERY-ORIENTED CANCER RESEARCH FOCUSED ON UNDERSTANDING HOW AND WHY CELLS BECOME CANCEROUS, AND ON PUBLIC EDUCATION RELATING TO CANCER PREVENTION, DETECTION, AND TREATMENT. NFCR'S SCIENTISTS ARE DISCOVERING CANCER'S MOLECULAR MYSTERIES AND TRANSLATING THEIR DISCOVERIES INTO THERAPIES THAT HOLD THE HOPE FOR CURING CANCER. NFCR IS ABOUT RESEARCH FOR A CURE-CURES FOR ALL TYPES OF CANCER. FOR MORE INFORMATION, PLEASE VISIT WWW.NFCR.ORG. SUMMARY OF RESEARCH ACCOMPLISHMENTS THIS YEAR, NFCR-FUNDED SCIENTISTS MADE SIGNIFICANT DISCOVERIES THAT WILL HAVE A LASTING INFLUENCE ON CANCER RESEARCH AND SAVE MANY LIVES DOWN THE ROAD. BELOW IS A SUMMARY OF SELECT SCIENTIFIC ACCOMPLISHMENTS IN 2010: DEVELOPMENT AND OPTIMIZATION OF 25 NOVEL RESEARCH TOOLS AND TECHNOLOGIES. PROGRESS IN THIS AREA IS CRITICAL FOR IMPROVING ANTI-CANCER DRUG SCREENING, BRINGING NEW DRUGS TO THE MARKETPLACE, AND IMPROVING CANCER TREATMENTS. IDENTIFICATION OF 30 NEW DRUG CANDIDATES. ALL OF THESE ANTICANCER AGENTS HAVE THE POTENTIAL TO BECOME, AND SOME WILL BECOME, EFFECTIVE TREATMENT OPTIONS, IMPROVING ON ANYTHING CURRENTLY AVAILABLE. THESE POTENTIAL CANCER THERAPEUTICS WILL BE FURTHER EVALUATED AND DEVELOPED IN THE COMING YEAR. IDENTIFICATION AND CHARACTERIZATION OF 11 CANCER BIOMARKERS. FURTHER DEVELOPMENT OF THESE CHARACTERISTIC MOLECULES IS CRUCIAL FOR EARLY DIAGNOSIS AND PERSONALIZED TREATMENT. 12 CLINICAL TRIALS CONDUCTED TO ADVANCE NEW DRUGS OR NEW TREATMENTS FROM THE LABORATORY RESEARCH PHASE INTO CLINICAL DEVELOPMENT. IDENTIFICATION AND EVALUATION OF 3 DIETARY NUTRIENTS THAT MAY HAVE POTENTIAL THERAPEUTIC PROPERTIES FOR USE IN CANCER PREVENTION AND TREATMENT. PUBLISHED MORE THAN 124 RESEARCH PAPERS IN INTERNATIONAL, PEER-REVIEWED SCIENCE JOURNALS THAT HAVE MADE SIGNIFICANT CONTRIBUTIONS TO OUR UNDERSTANDING OF THE COMPLEX NATURE OF CANCER. HIGHLIGHTS OF NFCR-FUNDED CANCER RESEARCH AND PUBLIC EDUCATION INITIATIVES IN 2010 IN LABORATORIES ACROSS THE UNITED STATES, EUROPE, AND CHINA, NFCR SCIENTISTS AND THEIR RESEARCH TEAMS ARE WORKING AT THE CUTTING-EDGE OF CANCER RESEARCH TODAY. HIGHLIGHTED HERE IS A SAMPLING OF THE IMPORTANT RESEARCH BREAKTHROUGHS IN CANCER PREVENTION, DETECTION, AND TREATMENT, AND THE COMPLEMENTARY PUBLIC EDUCATION CAMPAIGNS THAT INFORM THE PUBLIC ABOUT THESE LIFE-SAVING DISCOVERIES. CANCER PREVENTION STOPPING CANCER BEFORE IT STARTS IS THE BEST WAY TO HELP FAMILIES AROUND THE WORLD FROM HEARING THOSE THREE DEVASTATING WORDS, "YOU HAVE CANCER." BECAUSE AN ESTIMATED ONE-THIRD OF ALL CANCERS CAN BE PREVENTED, NFCR IS WORKING AROUND THE CLOCK TO RESEARCH HOW CANCER STARTS IN THE FIRST PLACE, SO THAT WE CAN PUT A STOP TO IT. BELOW ARE SOME HIGHLIGHTS OF NFCR RESEARCH ON CANCER PREVENTION. DEVELOPING NEW DRUGS TO PREVENT PANCREATIC CANCER. VERY FEW PANCREATIC CANCER PATIENTS LIVE FIVE YEARS FOLLOWING THEIR INITIAL DIAGNOSIS. CONSIDERED TO BE "THE FATHER OF CHEMOPREVENTION" FOR HIS PIONEERING USE OF DRUGS THAT FEND OFF CANCER AND OTHER DISEASES, MICHAEL SPORN, M.D., AT DARTMOUTH MEDICAL SCHOOL (NEW HAMPSHIRE) BELIEVES THAT CHEMOPREVENTION IS THE BEST AND MOST PRACTICAL WAY TO MEET THIS CHALLENGE OF PANCREATIC CANCER. HIS TEAM HAS NOW DEMONSTRATED THAT THEIR SYNTHETIC TRITERPENOIDS DRUGS HAVE PREVENTATIVE EFFECTS AGAINST PANCREATIC CANCER FORMATION IN A COMPLEX MODEL. BECAUSE THE SAME GENETIC DEFECTS IN THE MODEL ARE ALSO FOUND IN MANY PANCREATIC CANCER PATIENTS, WITH CONTINUED SUCCESS, THESE TRITERPENOIDS CAN RAPIDLY ENTER CLINICAL TRIALS FOR TREATING INDIVIDUALS AT HIGH RISK OF DEVELOPING PANCREATIC CANCER. DISCOVERING NATURAL PRODUCTS THAT MAY PREVENT SKIN CANCER. DR. HELMUT SIES (GERMANY) RECENTLY DEMONSTRATED THAT CERTAIN MARINE FISH HAVE A SUPERIOR ANTI-OXIDATIVE COMPOUND THAT PROTECTS SKIN CELLS FROM THE OXIDATIVE DAMAGES PRODUCED BY EXPOSURE TO UV LIGHT. OXIDATION-THE DAMAGE TO CELLS BY FREE RADICAL COMPOUNDS-IS THE LARGEST ENVIRONMENTAL CAUSE OF CANCER. DR. SIES IS WELL-RECOGNIZED FOR HIS RESEARCH ON THE CANCER PREVENTION EFFECTS OF LYCOPENE, THE ANTIOXIDANT FOUND IN TOMATOES AND CARROTS. AS A WORLD-RENOWNED BIOCHEMIST AND NATURAL PRODUCTS EXPERT, DR. SIES' FINDINGS CONTINUOUSLY ENHANCE PUBLIC AWARENESS OF MAINTAINING A HEALTHY DIET FOR CANCER PREVENTION. INVESTIGATING DIETARY SELENIUM AND COLORECTAL CANCER-PREVENTION. THE DIETARY MICRONUTRIENT, SELENIUM, IS INCORPORATED INTO SELENOPROTEINS THAT HAVE ANTI-OXIDATIVE FUNCTIONS TO KEEP OUR BODIES HEALTHY. DIETARY SELENIUM HAS BEEN SHOWN TO HAVE A BENEFICIAL IMPACT IN CLINICAL STUDIES FOR PREVENTION AND THERAPY OF COLORECTAL CANCER. HOWEVER, THE MOLECULAR BASIS FOR ITS EFFECTS IS NOT CLEARLY UNDERSTOOD. DR. HELMUT SIES (GERMANY), A WORLD-RENOWNED EXPERT ON CANCER-PREVENTIVE EFFECTS OF MICRONUTRIENTS, IS RESEARCHING A ROLE OF THE ANTI-OXIDANT SELENOPROTEINS IN THE PROGRESSION OF INFLAMMATORY BOWEL DISEASE (IBD) TO COLORECTAL CANCER. IN TUMOR MODELS OF IBD, HE IDENTIFIED INFLAMMATORY MOLECULES THAT DECREASED THE SYNTHESIS OF SELENOPROTEINS. A REDUCTION IN LEVELS OF SELENOPROTEINS MAY DIMINISH THE TOTAL ANT-OXIDANT CAPACITY OF THE INTESTINAL CELLS, ALLOWING IBD TO PROGRESS TO COLORECTAL CANCER. DR. SIES' IMPORTANT FINDINGS ARE LAYING THE GROUNDWORK FOR THE MOLECULAR BASIS OF HOW SELENIUM AND SELENOPROTEINS MAY PLAY A ROLE IN PREVENTING THIS FORM OF COLORECTAL CANCER. PREDICTING THE DEVELOPMENT OF SMOKING-RELATED LUNG CANCER IN HIGH-RISK PATIENTS. WAUN KI HONG, M.D., M.D. ANDERSON CANCER CENTER (TEXAS) IS A WORLD RENOWNED CANCER RESEARCHER ON THE ROLE OF SMOKING ON LUNG CANCER DEVELOPMENT. DR. HONG IS LEADING HIS TEAM IN BUILDING "RISK PREDICTION MODELS" FROM RESULTS OF THEIR CLINICAL TRIALS AND COLLECTIVE RESEARCH WHICH INCLUDES IDENTIFYING PROGNOSTIC BIOMARKERS, GENETIC VARIATIONS THAT MAY INDICATE PATIENTS AT RISK FOR LUNG CANCER RECURRENCE, AND CHEMOPREVENTION AGENTS. THE RESEARCH HAS IDENTIFIED 21 (TWENTY-ONE) BIOMARKERS THAT IS LEADING TO AN UNDERSTANDING OF TUMOR DEVELOPMENT IN SMOKING-RELATED LUNG CANCER. THE RESULTS OF THEIR ONGOING ANALYSIS WILL SERVE AS THE FOUNDATION FOR THE NEXT PHASE, A PROGRAM ON CHEMOPREVENTION IN LUNG CANCER. DR. HONG ENVISIONS THAT CLINICIANS MAY SOON BE ABLE TO PROVIDE PERSONALIZED CHEMOPREVENTION PROGRAMS FOR THE BEST CARE FOR SMOKERS OR PREVIOUS SMOKERS WHO ARE AT HIGH RISK TO DEVELOP LUNG CANCER OR FOR THEIR CANCER TO RETURN. ADDITIONAL RESEARCH ON CANCER PREVENTION INCLUDES: INVESTIGATING THE CANCER PREVENTION EFFECTS OF DNA INTERCALATING AGENTS. JANOS LADIK, PH.D., UNIVERSITY ERLANGEN-NURNBERG (GERMANY). IN ADDITION TO FUNDING LIFE-SAVING CANCER PREVENTION RESEARCH, NFCR IS ALSO COMMITTED TO INFORMING THE PUBLIC ABOUT MAKING HEALTHY LIFESTYLE CHOICES THAT CAN HELP SAVE SOMEONE FROM GOING THROUGH THE ORDEAL OF CANCER - CHOICES WHICH MAY HELP SAVE A LIFE. HEALTHY RECIPES: ONE OF THE MOST IMPORTANT FACTORS IN A HEALTHY LIFESTYLE IS DIET. FOR YEARS, NFCR HAS BEEN PROVIDING HEALTHY RECIPES EACH MONTH TO VISITORS TO OUR WEBSITE, WWW.NFCR.ORG, AND SUBSCRIBERS TO OUR E-NEWSLETTER. NFCR HAS AMASSED A COLLECTION OF OVER 200 HEALTHY RECIPES, WHICH ARE DISTRIBUTED TO OVER 35,000 PEOPLE EACH MONTH. ON YOUR HEALTH SERIES: NFCR CONTINUALLY WRITES AND POSTS ARTICLES RELATING TO UPDATES IN CANCER PREVENTION, WITH TITLES SUCH AS TEA: THE LATEST WEAPON AGAINST CANCER, SEEK SHADE NOT SUN, WHAT HAPPENS WHEN YOU SMOKE A CIGARETTE, AND WEIGH LESS, LIVE LONGER. THESE ARTICLES WERE BEEN READ OVER 177,000 TIMES IN 2009. ON YOUR HEALTH NOTE CARDS: ARTISTICALLY DESIGNED NOTE CARDS ENCOURAGE NFCR DONORS TO STAY IN TOUCH WITH THEIR FAMILIES AND FRIENDS WHILE SHOWING SUPPORT FOR NFCR'S LIFE-SAVING CANCER RESEARCH PROGRAMS. CANCER PREVENTION PRESS RELEASES: NFCR PROVIDES UP-TO-DATE NEWSFLASHES ABOUT WHAT CAN BE DONE TO BE BETTER PROTECTED AGAINST CANCER. THESE PUBLIC EDUCATION PRESS RELEASES HAVE RECEIVED OVER 20 MILLION IMPRESSIONS. NEWSLETTER: OUR COMPREHENSIVE RESEARCH FOR A CURE NEWSLETTER INCLUDES IN-DEPTH INFORMATION ABOUT VARIOUS METHODS OF CANCER PREVENTION. EACH ISSUE IS SENT TO OVER 125,000 PEOPLE. E-NEWSLETTER: THE MONTHLY ELECTRONIC NEWSLETTER RESEARCH FOR A CURE INCLUDES USEFUL REMINDERS ABOUT CANCER PREVENTION TIPS, AND IS SENT TO OVER 35,000 PEOPLE EACH MONTH. INSERTS IN OUR DIRECT MAIL PACKAGES: NFCR MAILINGS INCLUDE SEASONAL HEALTHY EATING RECIPES AND THE NUTRITIONAL BENEFITS OF DIFFERENT FRUITS AND VEGETABLES, AND OTHER PREVENTION TIPS. | FORM 990, PART II, LINES 4A AND 4B |
| CANCER DETECTION FOR MANY TYPES OF CANCER, EARLY DETECTION IS KEY. IF THE CANCER CAN BE REMOVED AND TREATED BEFORE IT SPREADS, OR METASTASIZES, THE PATIENT HAS A MUCH BETTER CHANCE AT LIVING A LONGER, CANCER-FREE LIFE. THAT'S WHY NFCR SCIENTISTS ARE WORKING ON NEW AND MORE EFFECTIVE WAYS TO DETECT CANCER EARLIER. BELOW ARE SOME HIGHLIGHTS OF OUR RESEARCH ON CANCER DETECTION. TRACKING CANCER IN REAL-TIME WITH A BREAKTHROUGH TECHNOLOGY. DANIEL A. HABER, M.D., PH.D., AT MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA, AND HIS TEAM OF SCIENTISTS HAVE DEVELOPED A REVOLUTIONARY WAY TO DETECT AND CAPTURE CIRCULATING TUMOR CELLS (CTCS) IN THE BLOOD. THIS TECHNOLOGY MAY PROVIDE DOCTORS WITH AN UNPRECEDENTED MEANS OF RAPIDLY DETECTING INVASIVE CANCERS BY USING AN EASY TO ADMINISTER BLOOD TEST. KNOWING ABOUT THE PRESENCE AND THE GENETIC FEATURES OF CANCER CELLS IN A PATIENT'S BLOOD MAY ENABLE THE PHYSICIAN TO IDENTIFY AND PRESCRIBE TARGETED ANTI-CANCER TREATMENTS EARLY ON, BEFORE THE DISEASE CAN SPREAD AND THEN RESIDE IN ANOTHER ORGAN. SUCH A TEST COULD ALSO ENABLE DOCTORS TO MONITOR THE EFFECTIVENESS OF THEIR PATIENT'S TREATMENT AND MAKE ANY NECESSARY TREATMENT CHANGES, INCREASING THE POSITIVE EFFECT OF ALL CANCER THERAPIES. ADVANCEMENTS IN IMAGING TECHNOLOGIES TO DETECT EARLY CHANGES IN CANCER CELLS. JAMES BASILION, PH.D., AND HIS COLLEAGUES AT THE NFCR CENTER FOR MOLECULAR IMAGING (OHIO) ARE ESTABLISHING A NEW TECHNOLOGY PLATFORM - MOLECULAR IMAGING FOR EARLY DETECTION AND IMPROVED TREATMENT OF CANCER. HIGHLY SENSITIVE IMAGING TOOLS ARE BEING DEVELOPED THAT CAN DETECT MULTIPLE MOLECULAR MARKERS SPECIFIC TO CANCERS SUCH AS BREAST, PROSTATE, AND BRAIN CANCER. UTILIZING AN ENTIRELY NEW TECHNIQUE THAT PERMITS THE SIMULTANEOUS IMAGING OF MULTIPLE MOLECULAR MARKERS, SCIENTISTS IN THIS CENTER MAKE IT POSSIBLE TO IDENTIFY CANCER AT A VERY EARLY AND MORE TREATABLE STAGE, SIGNIFICANTLY IMPROVING PATIENTS' CHANCES OF SURVIVAL. BLOOD BIOMARKERS FOR PREDICTING PROGNOSIS OF COLORECTAL CANCER. WEI ZHANG, PH.D., AT MD ANDERSON CANCER CENTER, HOUSTON, TX, IS CONDUCTING AN IN-DEPTH INVESTIGATION OF SMALL PIECES OF RNA (MICRORNAS) THAT ARE DETECTED IN THE BLOOD THAT MAY SERVE AS BIOMARKERS FOR COLORECTAL CANCER. USING BLOOD SAMPLES FROM HEALTHY DONORS AND PATIENTS WITH STAGE I THROUGH IV COLORECTAL CANCER, DR. ZHANG AND HIS TEAM HAVE DETERMINED ONE MICRORNA THAT MAY PREDICT PROGNOSIS FOR STAGE IV COLORECTAL CANCER PATIENTS. MOREOVER, THE MICRORNA WAS FOUND IN BLOOD SAMPLES OF PATIENTS FROM TWO ETHNIC POPULATIONS, STRENGTHENING ITS VALIDITY AS A BIOMARKER. MICRORNAS MAY REPRESENT A KEY ADVANCEMENT IN THE SEARCH FOR VALUABLE BLOOD BIOMARKERS FOR COLON CANCER THAT MAY BE TRANSLATED INTO CLINICAL APPLICATIONS INCLUDING PROGNOSIS, MONITORING RESPONSE TO THERAPY, AND DETECTING DISEASE RECURRENCE TO SAVE PATIENTS' LIVES. ADDITIONAL RESEARCH ON CANCER DETECTION INCLUDES: SUCCESSFUL DEVELOPMENT OF NEW HIGH THROUGHPUT PROTEIN ARRAY DETECTION METHOD TO IDENTIFY PATIENTS WITH EARLY STAGE CANCER. LAWRENCE MARNETT, PH.D., DANIEL LIEBLER, PH.D., RICHARD CAPRIOLI, PH.D, VANDERBILT UNIVERSITY (TENNESSEE) DEVELOPMENT OF INHIBITORS OF A GENE HIGHLY RELATED TO INITIATION AND PROGRESSION OF PANCREATIC AND LIVER CANCER. DANIEL VON HOFF, M.D., LAURENCE HURLEY, PH.D., TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (ARIZONA) IN ADDITION TO OUR FOCUS ON RESEARCH, THE NFCR TEAM IS COMMITTED TO KEEPING THE PUBLIC UP-TO-SPEED ON CANCER SCREENINGS AND DIAGNOSTIC TESTS THAT CAN GREATLY INCREASE THE CHANCES OF CATCHING CANCER EARLY. EARLY CANCER DETECTION CHARTS: A DETAILED LIST OF 22 OF THE MOST COMMON CANCERS, THIS CHART CONTAINS INFORMATION ABOUT EACH CANCER'S SIGNS AND SYMPTOMS, AS WELL AS DIAGNOSTIC AIDES. THIS IS OUR MOST REQUESTED PUBLICATION. CHILDHOOD DETECTION CANCER CHART: PROVIDES CONCISE AND COMPREHENSIVE EARLY WARNING SIGNS OF CHILDHOOD CANCERS TO HELP PARENTS RECOGNIZE SYMPTOMS AND BEHAVIORS ASSOCIATED WITH DIFFERENT TYPES OF CHILDHOOD CANCER. THIS PUBLICATION WAS FUNDED BY A GRANT FROM THE LUDCKE FOUNDATION OF BOSTON, MASSACHUSETTS AND HAS BEEN DISTRIBUTED TO OVER 200,000 FAMILIES. SCREENING TOOLS: NFCR OFFERS INFORMATION ON SCREENING TOOLS - CERTAIN EXAMINATIONS OR TESTS IN PEOPLE WHO DO NOT HAVE ANY SYMPTOMS OF CANCER, BUT ARE AT HIGH RISK FOR DEVELOPING CERTAIN TYPES OF CANCER. THIS INCLUDES INFORMATION ON GENETIC TESTING, PLUS SPECIFIC SCREENING INFORMATION FOR BREAST, CERVICAL, COLON, LUNG, OVARIAN, PROSTATE, AND UTERINE CANCER. DIAGNOSTIC AND MONITORING TESTS. NFCR OFFERS INFORMATION ON DIAGNOSTIC TESTS, WHICH DIAGNOSE AND MONITOR CANCER PROGRESSION. THIS INCLUDES INFORMATION ON PATHOLOGY TESTS, DIAGNOSTIC IMAGING, BLOOD TESTS, TUMOR MARKERS, AND GENOMICS. CANCER TREATMENT IT'S EXTREMELY SATISFYING TO MAKE A RESEARCH DISCOVERY; BUT THE MOST SATISFYING IS TO KNOW THAT OUR RESEARCH DISCOVERIES ARE HELPING PEOPLE AROUND THE WORLD. TRANSLATING BREAKTHROUGHS IN THE LABORATORY INTO LIFE-SAVING TREATMENTS IS MAKING A DIFFERENCE - TO CANCER PATIENTS AND TO THE PEOPLE WHO LOVE THEM. INNOVATIVE GENE THERAPY FOR METASTATIC PROSTATE CANCER. NFCR SCIENTIST PAUL B. FISHER, M.PH., PH.D., AT VIRGINIA COMMONWEALTH UNIVERSITY IN RICHMOND, VIRGINIA, HAS DEVELOPED A POTENTIAL TARGETED CANCER THERAPY FROM A GENETICALLY REPROGRAMMED VIRUS CALLED "CANCER TERMINATOR VIRUS" (CTV). A SPECIAL GENE ELEMENT DISCOVERED BY DR. FISHER IS INCORPORATED IN CTV AND ALLOWS IT TO TARGET AND REPLICATE ONLY IN TUMOR CELLS, AN EFFECT THAT WOULD ALLEVIATE ANY DANGEROUS SIDE EFFECTS FROM KILLING HEALTHY CELLS, LIKE THOSE EFFECTS PRODUCED BY STANDARD CYTOTOXIC THERAPIES. CTV ALSO DELIVERS THE GENE FOR INTERFERON GAMMA (IFN?), OUR BODY'S IMMUNE MODULATING MOLECULE THAT WILL DIRECTLY ELICIT AN IMMUNE RESPONSE IN THE TUMOR AND ENERGIZE THE IMMUNE SYSTEM TO SEEK AND DESTROY ANY CANCER CELLS, INCLUDING THOSE THAT HAVE METASTASIZED. CTV WILL BE ESPECIALLY USEFUL FOR REFRACTORY PROSTATE CANCER PATIENTS WHOSE TUMORS HAVE STOPPED RESPONDING TO OTHER TREATMENTS, AND FOR THOSE WHOSE CANCER HAS METASTASIZED. PERSONALIZED MEDICINE FOR NON-SMALL CELL LUNG CANCER PATIENTS. WAUN KI HONG, M.D., AT MD ANDERSON CANCER CENTER, HOUSTON, TX, IS A WORLD-RENOWNED RESEARCHER WHO INITIATED THE BATTLE PROGRAM, OR BIOMARKER-BASED APPROACHES OF TARGETED THERAPY FOR LUNG CANCER ELIMINATION TO DEVELOP INDIVIDUALIZED TARGETED THERAPIES FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS RESISTANT TO CHEMOTHERAPY. RECENTLY, DR. HONG'S TEAM PRESENTED VERY ENCOURAGING RESULTS OF FOUR (4) CLINICAL TRIALS THAT TESTED PERSONALIZED MEDICINE PROTOCOLS IN LUNG CANCER PATIENTS. IN THESE TRIALS, PATIENTS WERE ASSIGNED TO THE TREATMENT DRUG WHICH THEY WERE MOST LIKELY TO RESPOND BASED ON THEIR PERSONAL BIOMARKER PROFILE IDENTIFIED THROUGH TUMOR BIOPSIES. BATTLE IS AN IMPORTANT STEP TOWARD PERSONALIZED MEDICINE AND MARKS A PARADIGM SHIFT FOR CLINICAL TRIALS BY DEMONSTRATING THE FEASIBILITY OF A BIOPSY-BASED, BIOMARKER TRIAL. THESE INITIATIVES WILL MOVE PERSONALIZED MEDICINE FORWARD AND IMPROVE TREATMENT EFFICACY TO INDIVIDUAL PATIENTS. ANTI-ANGIOGENESIS: SHUTTING DOWN CANCER. PAUL SCHIMMEL, PH.D., AND COLLEAGUES AT THE SCRIPPS RESEARCH INSTITUTE, LA JOLLA, CA, ARE SEEKING TO UNDERSTAND WHY HUMAN AMINO ACYL TRNA SYNTHETASES, ONE OF THE ESSENTIAL ENZYMES OF PROTEIN SYNTHESIS MACHINERY FOUND IN ALL ORGANISMS, HAVE DISTINCT ADDITIONAL VITAL ACTIVITIES, THAT ARE INVOLVED IN PATHWAYS RELEVANT TO TREATING CANCER AND OTHER DISEASES. IN THE PAST YEAR, THE SCIENTISTS PUBLISHED A LANDMARK PAPER ON THEIR DISCOVERY OF HOW ONE TRNA SYNTHETASE INHIBITS BLOOD VESSEL FORMATION, POTENTIALLY FUELING DEVELOPMENT OF NEW ANTI-ANGIOGENESIS TREATMENTS WHICH HAVE BEEN SO EFFECTIVE IN KEEPING CANCER FROM GROWING AND SPREADING. NEW ANTIBODIES THAT TARGET KIDNEY CANCER OPENS DOOR FOR NOVEL THERAPY. WAYNE MARASCO, M.D., PH.D., AT THE DANA-FARBER CANCER INSTITUTE, HARVARD MEDICAL SCHOOL, CAMBRIDGE, MA, IS DISCOVERING AND ENGINEERING THERAPEUTIC ANTIBODIES FOR CANCER RESEARCH AND CLINICAL APPLICATIONS. PREVIOUS RESEARCH ESTABLISHED A LIBRARY CONTAINING 1.6 BILLION DIFFERENT HUMAN SFV ANTIBODY-DISPLAYING PHAGES, A TREMENDOUS RESOURCE FOR DEVELOPING MONOCLONAL ANTIBODY-BASED TARGETED THERAPIES. IN THE PAST YEAR, HE HAS LED HIS TEAM TO IDENTIFY HIGH AFFINITY HUMAN SFV ANTIBODIES AGAINST A UNIQUE DOMAIN OF A SELECTED CANCER TARGET FOR RENAL CELL CARCINOMA. THESE REAGENTS HOLD PROMISE FOR NEW IMMUNOTHERAPIES AND DIAGNOSTIC TOOLS FOR KIDNEY CANCER PATIENTS. DISCOVERING NEW BIOMARKERS AND THERAPIES: STOPPING FORMATION OF BLOOD VESSELS THAT SUPPORT GROWTH OF ALL TYPES OF TUMORS . HAROLD DVORAK, M.D. BETH ISRAEL DEACONESS MEDICAL CENTER, HARVARD MEDICAL SCHOOL (MASSACHUSETTS) NEW STRATEGIES TO OVERCOME DRUG RESISTANCE TO TAXOL FOR BREAST CANCER PATIENTS. SUSAN BAND HORWITZ, PH.D., ALBERT EINSTEIN COLLEGE OF MEDICINE (NEW YORK) | ||
| NEW STRATEGIES TO OVERCOME DRUG RESISTANCE TO TAXOL FOR BREAST CANCER PATIENTS. SUSAN BAND HORWITZ, PH.D., ALBERT EINSTEIN COLLEGE OF MEDICINE (NEW YORK) NEWLY DISCOVERED ANTI-VIRAL COMPOUNDS AND NATURAL PRODUCTS THAT HAVE ANTICANCER ACTIVITY IN LIVER CANCER. YUNG-CHI CHENG, M.D., YALE UNIVERSITY (CONNECTICUT) ADVANCES IN THE WORLD'S LARGEST COMPUTATIONAL DRUG SCREENING TECHNOLOGY FOR ACCELERATED IDENTIFICATION OF NEW CANCER DRUGS. W. GRAHAM RICHARDS, D.SC., UNIVERSITY OF OXFORD (UNITED KINGDOM) DEVELOPING NEW TREATMENT FOR ACUTE MYELOID LEUKEMIA (AML). CURT CIVIN, M.D., UNIVERSITY OF MARYLAND, BALTIMORE. TUMOR-TARGETING IMMUNOTHERAPY FOR LYMPHOMA. LAURENCE COOPER, M.D., PH.D., M.D. ANDERSON CANCER CENTER (TEXAS) NEW DRUG INTERVENTIONS FOR SOFT TISSUE SARCOMAS. DINA LEV, M. D., MD ANDERSON CANCER CENTER (TEXAS) DEVELOPMENT OF INHIBITORS OF A CANCER PATHWAY THAT SENSITIZE PANCREATIC CANCER TO TARGETED THERAPY- A NEW COMBINATION TREATMENT. . DANIEL VON HOFF, M.D., TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (ARIZONA) DISSECTING MOLECULAR CHANGES INVOLVED IN METASTASIS OF SKIN CANCER: DEVELOPING THERAPIES TO STOP THE LETHAL SPREAD. DANNY WELCH, PH.D., UNIVERSITY OF ALABAMA IDENTIFYING MARKERS TO PREDICT THE EFFECT OF ANTI-ANGIOGENIC THERAPY FOR BRAIN CANCER PATIENTS. RAKESH JAIN, PH.D., MASSACHUSETTS GENERAL HOSPITAL IMPROVING TREATMENT OPTIONS FOR CANCER PATIENTS IS JUST ONE STEP IN THE JOURNEY. IT IS ALSO IMPORTANT TO HELP EDUCATE PATIENTS AND ONCOLOGISTS ABOUT THE LATEST TREATMENT OPTIONS MADE POSSIBLE THROUGH RESEARCH. BELOW ARE JUST SOME OF THE WAYS THAT NFCR IS SERVING COMMUNITIES BY SHARING THE LATEST NEWS IN CANCER TREATMENT. TREATMENT DECISION TOOLS: IN PARTNERSHIP WITH US ONCOLOGY, NFCR OFFERS FREE ONLINE TREATMENT DECISION TOOLS AT WWW.NFCR.ORG/PATIENTSUPPORT TO HELP CANCER PATIENTS MAKE MORE EDUCATED DECISIONS WITH THEIR PHYSICIANS. HIGHLY RECOGNIZED ONCOLOGISTS MATRIX: THIS RESOURCE PROVIDES NFCR DONORS AND FAMILIES A LIST OF NFCR-RECOMMENDED ONCOLOGISTS IN THE U.S. SO THAT THEY CAN ACCESS THE BEST ADVANCED CANCER CARE AVAILABLE. TYPES OF TREATMENT. NFCR OFFERS INFORMATION ON DIFFERENT TYPES OF TREATMENT, INCLUDING CHEMOTHERAPY, RADIATION THERAPY, SURGERY, HORMONAL THERAPY, TARGETED THERAPY, COMPLEMENTARY & ALTERNATIVE THERAPY, AND THE SIDE EFFECTS OF TREATMENT. CLINICAL TRIALS. NFCR OFFERS INFORMATION ON CLINICAL TRIALS, INCLUDING PHASES OF CLINICAL TRIALS, CLINICAL TRIAL SAFEGUARDS, THE COST OF CLINICAL TRIALS, AND FINDING SPECIFIC CLINICAL TRIALS. CANCER HEADLINES. NFCR TRACKS AND PUBLISHES THE LATEST IN CANCER HEADLINES TO EDUCATE THE PUBLIC ABOUT UP-AND-COMING TREATMENTS. NFCR FUNDED RESEARCHERS IN 2010 NFCR HAS BUILT A SCIENCE PROGRAM THAT NOW INVOLVES NEARLY 50 TOP RESEARCH LABORATORIES IN THE U.S. AND OTHER COUNTRIES AROUND THE WORLD. TO MAXIMIZE THE VALUE OF OUR RESOURCES AND WORK MORE EFFICIENTLY, NFCR ORGANIZES ITS SCIENCE PROGRAM USING THREE DIFFERENT FUNDING STRUCTURES, NAMELY THE NFCR RESEARCH DISCOVERY CENTERS, NFCR FELLOWS, AND NFCR PROJECT DIRECTORS. NFCR RESEARCH DISCOVERY CENTERS ARE THE CORE OF OUR RESEARCH NETWORK. THEY PROVIDE THE PLATFORM FOR COLLABORATION. NFCR HAS ESTABLISHED EIGHT CENTERS EQUIPPED WITH CUTTING-EDGE TECHNOLOGIES AND EACH WITH THEIR OWN FOCUS ON ONE OR MORE OF THE MOST CRITICAL RESEARCH FRONTS. BELOW IS THE LIST OF THE NFCR CENTERS AND EACH OF THEIR DIRECTORS, WHO ARE ONE OR MORE HIGHLY ACCOMPLISHED CANCER RESEARCH LEADERS. NFCR FELLOWS ARE DISTINGUISHED AND WELL-ESTABLISHED SCIENTISTS WHO HAVE EXCELLENT TRACK RECORDS IN THEIR FIELDS OF SCIENTIFIC INTEREST. NFCR PROVIDES THEM WITH MULTIPLE YEARS OF UNRESTRICTED FUNDING TO ALLOW THE NURTURING OF THEIR DISCOVERY-ORIENTED RESEARCH. NFCR PROJECT DIRECTORS ARE OUTSTANDING RESEARCHERS WHO ARE TAKING RISKS TO EXPLORE NEW RESEARCH FIELDS. NFCR PROVIDES "SEED FUNDING" TO THEIR PROJECT-BASED RESEARCH, PROVIDING THEM A PRECIOUS OPPORTUNITY TO VALIDATE THEIR INNOVATIVE IDEAS AND MOVE PROMISING RESEARCH FORWARD. NFCR IS ABOUT SAVING LIVES THE FINANCIAL SUPPORT OF 4 MILLION DONORS TO NFCR IS PAYING OFF. MORE INDIVIDUALS DIAGNOSED WITH CANCER ARE SURVIVING TODAY THAN EVER BEFORE, AND THOSE WHO UNFORTUNATELY DO NOT SURVIVE LIVE LONGER AND EXPERIENCE A MUCH BETTER QUALITY OF LIFE THAN WAS POSSIBLE JUST A FEW YEARS AGO. EVERY DAY AT NFCR, OUR RESEARCHERS REPORT PROGRESS IN DEVELOPING PROMISING NEW TREATMENTS FOR CANCER. BUT UNTIL THERE IS A CURE, WE WILL NOT BE SATISFIED-TOO MANY LIVES ARE AT STAKE. NFCR IS COMMITTED TO FUNDING RESEARCH BECAUSE WE WANT TO CURE CANCER. WE CONTINUE TO PURSUE EVERY QUALIFIED LEAD AND EVERY OPPORTUNITY THAT MERITS FUNDING WITH THE RESOURCES WE HAVE AVAILABLE. AS AN ORGANIZATION THAT RELIES SOLELY ON THE GENEROSITY OF MILLIONS OF DONORS NATIONWIDE, WE TAKE THE FIGHT AGAINST CANCER VERY SERIOUSLY. NO RISK IS TOO GREAT WHEN IT COMES TO SAVING LIVES! ADDITIONAL INFORMATION ABOUT THE NATIONAL FOUNDATION FOR CANCER RESEARCH CAN BE FOUND AT WWW.NFCR.ORG OR BY CALLING (800) 321-CURE (2873). |
Schedule R IRS990ScheduleR
Form990 Schedule R Part II Form990ScheduleRPartII (4 entries)
| Address Line1AddressUS/AddressLine1 | CityAddressUS/City | StateAddressUS/State | ZIP CodeAddressUS/ZIPCode | EINEIN | Primary ActivitiesPrimaryActivities | Legal Domicile StateLegalDomicileState | Exempt Code SectionExemptCodeSection | Public Charity StatusPublicCharityStatus | Business Name Line1DirectControllingEntityName/BusinessNameLine1 | Controlled OrgControlledOrg | Address Line1AddressForeign/AddressLine1 | CityAddressForeign/City | CountryAddressForeign/Country | Legal Domicile Foreign CountryLegalDomicileForeignCountry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FUND FOR INHERITED DISEASE RESEARCH INC | ||||||||||||||
| 4600 EAST-WEST HIGHWAY NO 525 | BETHESDA | MD | 20814 | 470852643 | CANCER RESEARCH | PA | 501(C)3 | 170(B)(1) (A)(V1) | NATIONAL FOUNDATION FOR CANCER RESEARCH | 0 | ||||
| ASIAN FUND FOR CANCER RESEARCH LIMITED | ||||||||||||||
| CANCER RESEARCH | NATIONAL FOUNDATION FOR CANCER RESEARCH | 0 | 5/F DAH SING LIFE BUILDING 99-105 | CENTRAL | HK | HK | ||||||||
| CONSORTIUM FOR CLINICAL DIAGNOSTICS | ||||||||||||||
| 4600 EAST-WEST HIGHWAY NO 525 | BETHESDA | MD | 20814 | 371473821 | CANCER RESEARCH | DC | 501(C)3 | 509(A)(3) | NATIONAL FOUNDATION FOR CANCER RESEARCH | 0 | ||||
| RESEARCH FOR A CURE | ||||||||||||||
| 4600 EAST-WEST HIGHWAY NO 525 | BETHESDA | MD | 20814 | 010744146 | CANCER RESEARCH | DC | 501(C)3 | 509(A)(3) | NATIONAL FOUNDATION FOR CANCER RESEARCH | 0 | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Ann Rents Royalties | 0 | ReceiptOfIntAnnRentsRoyalties |
| Gift Grant Or Cap Contr To Other Org | 0 | GiftGrantOrCapContrToOtherOrg |
| Gift Grant Or Cap Contr Fr Other Org | 0 | GiftGrantOrCapContrFrOtherOrg |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrg |
| Loans Or Guarantees From Other Org | 0 | LoansOrGuaranteesFromOtherOrg |
| Sale Of Assets To Other Org | 0 | SaleOfAssetsToOtherOrg |
| Purchase Of Assets From Other Org | 0 | PurchaseOfAssetsFromOtherOrg |
| Exchange Of Assets | 0 | ExchangeOfAssets |
| Rental Of Facilities To Other Orgs | 0 | RentalOfFacilitiesToOtherOrgs |
| Rental Of Facilities Fr Other Orgs | 0 | RentalOfFacilitiesFrOtherOrgs |
| Perform Of Services For Other Orgs | 0 | PerformOfServicesForOtherOrgs |
| Perform Of Services By Other Orgs | 0 | PerformOfServicesByOtherOrgs |
| Sharing Of Facilities | 0 | SharingOfFacilities |
| Sharing Of Paid Employees | 1 | SharingOfPaidEmployees |
| Reimbursement Paid To Other Org | 0 | ReimbursementPaidToOtherOrg |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrg |
| Other Transfer To Other Org | 0 | OtherTransferToOtherOrg |
| Other Transfer From Other Org | 0 | OtherTransferFromOtherOrg |
Comments